Fluzone® Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults
Fluzone® Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults
复制标题
DOI：
10.1586/erv.11.154
复制
发表时间：
2012-01-01
影响因子：
6.2
通讯作者：
Icardi, Giancarlo
中科院分区：
文献类型：
--
作者：
Ansaldi, Filippo;de Florentiis, Daniela;Icardi, Giancarlo
2011年5月9日，美国FDA批准了赛诺菲巴斯德的Fluzone（R）皮内流感疫苗，这是美国批准的第一种使用新型显微注射系统进行疫苗皮内递送的流感疫苗（Soluvia（TM），Becton Dickinson）。它的抗原含量（每株9 μ g血凝素）低于常规肌内疫苗（15 μ g），适用于18 - 64岁成人的主动免疫。来自评估Fluzone Intradermal在成人中的免疫原性和安全性的临床试验的数据与Intanza（R）9 μ g积累的大量经验一致，Intanza（R）9 μ g是2009年2月26日获得许可并于2010/2011年季节在欧洲上市的皮内疫苗。Fluzone Intradermal是安全的，其免疫原性与常规肌内疫苗相当。获得皮内疫苗的最佳可接受性可能是帮助增加年轻人流感疫苗接种覆盖率的额外资产。
On May 9 2011, the US FDA approved Sanofi Pasteur's Fluzone (R) Intradermal influenza vaccine, the first influenza vaccine licensed in the USA that uses a new microinjection system for intradermal delivery of vaccines (Soluvia (TM), Becton Dickinson). Its antigen content is lower (9 mu g hemagglutinin per strain) than the conventional intramuscular vaccine (15 mu g) and it is indicated for active immunization of adults aged between 18 and 64 years. Data from the clinical trial assessing immunogenicity and safety of Fluzone Intradermal in adults were consistent with substantial experience accumulated with Intanza (R) 9 mu g, the intradermal vaccine licensed on February 26 2009 and launched during the 2010/2011 season in Europe. Fluzone Intradermal is safe and its immunogenicity comparable with that of conventional intramuscular vaccines. Obtaining optimal acceptability of intradermal vaccines may represent an additional asset to help increase the coverage of influenza vaccination in young adults.